These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35908959)

  • 1. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
    Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
    Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
    Mie T; Sasaki T; Takeda T; Fukuda K; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Pancreas; 2021 Apr; 50(4):595-601. PubMed ID: 33939674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
    Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
    BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
    Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
    Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
    Shibuki T; Otsuka T; Shimokawa M; Nakazawa J; Arima S; Fukahori M; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Makiyama A; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Nio K; Ide Y; Ureshino N; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 Jul; 14(1):16906. PubMed ID: 39043707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
    Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H
    Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
    Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
    Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
    JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
    Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH
    Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
    Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
    J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure.
    Okuno M; Mukai T; Iwata K; Takagi A; Ito Y; Ohashi Y; Tezuka R; Iwasa Y; Iwata S; Tomita E
    Med Oncol; 2024 Jul; 41(8):195. PubMed ID: 38967720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
    Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
    Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
    Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
    Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.